Skip to main content

Abstract

Purpose: This prospective, randomized, double-blind, placebo-controlled, parallel-group study aimed to determine the efficacy and safety of a multistrain (Bacillus coagulans [SNZ 1969], Bacillus clausii [SNZ 1971], and Bacillus subtilis [SNZ 1972]) probiotic blend (SNZ TriBac) in managing symptoms of gastrointestinal (GI) discomfort in the absence of specific pathologies.

Methods: Sixty adults with symptoms of GI discomfort were enrolled (mean age, 34.89 ± 9.95 years) and randomized to receive either SNZ TriBac or placebo. Changes from baseline in Severity of Dyspepsia Assessment (SODA), Gastrointestinal Symptom Rating Scale (GSRS), and Quality of Life (QoL) scales over the course of product use were determined at baseline and on days 30 and 37 as study outcomes.

Results: On day 30, significant improvement with SNZ TriBac was noted in SODA burping/belching (P = 0.025), bloating (P = 0.048), sour taste (P = 0.025), and total (P = 0.007) scores as well as pain (P = 0.003), non-pain (P = 0.04), and satisfaction (P = 0.03) subscores. Significant improvement with SNZ TriBac was also observed in SODA burping/belching (P = 0.011), sour taste (P = 0.011), and total SODA scores (P < 0.001), and in SODA pain (P = 0.005), non-pain (P = 0.06), and satisfaction (P = 0.004) subscores on day 37. No adverse events were reported.

Conclusion: Significant improvement in final SODA scores and subscores with SNZ TriBac versus placebo indicates improvement in several symptoms of gastrointestinal discomfort. This multistrain probiotic blend was well tolerated and could be an effective option for treatment of GI discomfort.

Trial registration: Clinical Trials Registry of India (CTRI/2018/05/014071).

Keywords: Bacillus clausii; Bacillus coagulans; Bacillus subtilis; Gastrointestinal discomfort; Probiotic.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bacillus clausii SNZ-1971Improved Total SODA ScoresBeneficial
Large
Bacillus clausii SNZ-1971No Adverse Events ObservedNeutral
Large
Bacillus clausii SNZ-1971Reduced Gastrointestinal Discomfort SymptomsBeneficial
Moderate
Bacillus coagulans SNZ-1969Improved SatisfactionBeneficial
Moderate
Bacillus coagulans SNZ-1969Improved Total SODA ScoresBeneficial
Large
Bacillus coagulans SNZ-1969Reduced BloatingBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Burping FrequencyBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Non-Pain SymptomsBeneficial
Moderate
Bacillus coagulans SNZ-1969Reduced Pain SymptomsBeneficial
Large
Bacillus coagulans SNZ-1969Reduced Sour Taste PerceptionBeneficial
Moderate
Bacillus subtilis SNZ-1972Reduced BloatingBeneficial
Moderate
Bacillus subtilis SNZ-1972Reduced Burping FrequencyBeneficial
Moderate
Bacillus subtilis SNZ-1972Reduced Gastrointestinal SymptomsBeneficial
Large
Bacillus subtilis SNZ-1972Reduced Non-Pain SymptomsBeneficial
Moderate
Bacillus subtilis SNZ-1972Reduced Pain LevelsBeneficial
Large
Bacillus subtilis SNZ-1972Reduced Sour Taste PerceptionBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.